All In MedTech

Device Trial Radar · NCT07926581

Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval

Prospective, Multicenter, International, Post-Market, Observational Study to Assess the Efficacy and Safety of Neurolyser XR

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 12, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
FUSMobile Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 9, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Neurolyser XR demonstrated positive outcomes in the clinical studies prior to obtaining CE marking, and well as in multiple pilot trials performed globally. This Post-Market Clinical Follow-up study is required to evaluate the safety and effectiveness of the Neurolyser XR under real-world conditions.

Conditions

  • Lumbar Zygapophyseal Pain
  • Low Back Pain
  • Facet Joint Pain; Low Back Pain

Interventions

  • High Intensity Focused UltrasoundDevice

    Use of high intensity focused ultrasound (HIFU), or ultrasound energy, to ablate the intended anatomical target.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness Endpoint - Assessed by change in Numeric Rating Scale (NRS)Time frame: Up to 12 Months post procedure
  2. Effectiveness Endpoint - Assessed by change in Patient's Global Impression of Pain (PGIC)Time frame: Up to 12 Months post procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinik Pm

    Alicante, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.